BROADENING THE DEFINITION OF TOLERABILITY IN CANCER CLINICAL TRIALS TO BETTER MEASURE THE PATIENT EXPERIENCE

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

whitePaper | May 23, 2022

The world’s scientific data today is a morass. 50-80% of research scientist and data scientist time is spent wrestling with data before they can focus on highervalue AI/ML and advanced analysis to help bring new life-saving therapeutics to market.